Government Grant

6 Months Ended

Jun. 30, 2020

Government Grants [Abstract]

Government Grant

9. Government Grant

In September 2019, the Company was awarded a two-year $1.0 million grant from the orphan drug office of the U.S. Food and Drug Administration to support the clinical development of avacopan in patients with the rare kidney disease complement 3 glomerulopathy. For the three and six months ended June 30, 2020, the Company recognized $0.2 million and $0.3 million of grant revenue, respectively. As of June 30, 2020, $0.2 million was recorded as accounts receivable.